Relmada Therapeutics

RLMD · NASDAQ

$3.36+$0.20 (+6.33%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $3.16

RLMD analyst rating

BuyConsensus of 6 analysts over the last 12 months. 100% rate it a buy.

Strong buy0
Buy6
Hold0
Underperform0
Sell0

12-month price target · 6 analysts

Average $10.97 (+226.3% upside)

Low: $9.09
Now: $3.36
High: $12.60

Upgrades and downgrades

The latest rating actions, newest first

RLMD analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
HC Wainwright & Co.	Jun 18, 2026	Initiates	Buy	$12.00	41%
Piper Sandler	Mar 24, 2026	Initiates	Overweight	$12.00	70%
Mizuho	Mar 20, 2026	Maintains	Outperform	$10.00 → $19.00	46%
LUCID CAPITAL MARKETS	Mar 2, 2026	Initiates	Buy	$14.00	50%
Leerink Partners	Jan 23, 2026	Upgrade	Market Perform → Outperform	$8.00	45%
Jefferies	Dec 22, 2025	Initiates	Buy	$9.00	60%
Mizuho	Nov 19, 2025	Upgrade	Neutral → Outperform	$1.00 → $10.00	46%

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.